|
Reloxaliase
|
DB15560 |
[Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).] |
|
Influenza A virus A/North carolina/04/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
|
DB15562 |
[A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.] |
|
Quinoline Yellow WS
|
DB14231 |
|
|
Valoctocogene roxaparvovec
|
DB15561 |
[Valoctocogene roxaparvovec is under investigation in clinical trial NCT03392974 (Single-arm Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia a Patients at a Dose of 4E13 Vg/kg).] |
|
Albumin Aggregated
|
DB14230 |
[Albumin Aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc 99m albumin aggregated injection.] |
|
3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
|
DB02259 |
|
|
Diphenylacetic Acid
|
DB03588 |
|
|
N-Bromoacetyl-Aminoethyl Phosphate
|
DB02257 |
|
|
Alpha-Ketomalonic Acid
|
DB03589 |
|
|
SR11254
|
DB02258 |
|
|
(3R,4R,5S,6R)-6-Fluoro-3,4,5-trihydroxytetrahydro-2H-pyran-2-olate
|
DB03586 |
|
|
GM6001
|
DB02255 |
|
|
Pyruvaldehyde
|
DB03587 |
[An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]] |
|
2'-Deoxyuridine
|
DB02256 |
[2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. [PubChem]] |
|
(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol
|
DB02253 |
|
|
4-Thio-beta-D-glucopyranose
|
DB03584 |
|
|
Oxyphenbutazone
|
DB03585 |
[Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.] |
|
Trifluoro-thiamin phosphate
|
DB02254 |
|
|
7-methyl-5'-guanylic acid
|
DB03593 |
|
|
Orotic Acid
|
DB02262 |
|
